stockportfolio.pro
Arbutus Biopharma Corporation (ABUS)
Healthcare · Biotechnology · NasdaqGS
Arbutus Biopharma Corporation revenue & earnings — last 10 fiscal years
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.49M | $10.70M | $5.95M | $6.01M | $6.91M | $10.99M | $39.02M | $18.14M | $6.17M | $14.08M |
| Gross profit | — | — | — | — | — | — | — | — | — | — |
| Net income | $-384.16M | $-84.41M | $-57.06M | $-153.72M | $-63.74M | $-76.25M | $-69.46M | $-72.85M | $-69.92M | $-33.50M |
| Net margin | -25765.5% | -788.9% | -959.8% | -2557.4% | -922.0% | -693.9% | -178.0% | -401.6% | -1133.0% | -237.9% |
Source: Arbutus Biopharma Corporation SEC filings (10-K). 15 years of history available in the interactive view.
Explore 15 years of Arbutus Biopharma Corporation financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track ABUS in your portfolio →
Arbutus Biopharma Corporation financial history by metric
About Arbutus Biopharma Corporation
Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reawaken patients' HBV-specific immune response by inhibiting PD-L1. The company has licensing agreement with Alnylam Pharmaceuticals, Inc. to develop and commercialize products with LNP delivery technology. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation was incorporated in 2005 is headquartered in Warminster, Pennsylvania.
Arbutus Biopharma Corporation — frequently asked questions
What is Arbutus Biopharma Corporation's revenue?
Arbutus Biopharma Corporation (ABUS) reported revenue of $14.08M for fiscal year 2025, up 128.2% from the prior year, according to its SEC filings.
Is Arbutus Biopharma Corporation profitable?
No — ABUS reported a net loss of $-33.50M in fiscal 2025.
What is ABUS's P/E ratio?
Arbutus Biopharma Corporation trades at a price-to-earnings ratio of about 5.1 based on the latest data in our nightly-refreshed cache.
How fast is Arbutus Biopharma Corporation growing?
ABUS's revenue grew at roughly 15.3% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
How much debt does Arbutus Biopharma Corporation have?
As of fiscal year 2025, ABUS carried roughly $0 in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Arbutus Biopharma Corporation's market cap?
Arbutus Biopharma Corporation (ABUS) has a market capitalization of about $833.61M, based on the latest data in our nightly-refreshed cache.
When does Arbutus Biopharma Corporation's fiscal year end?
ABUS's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
Where does this data come from?
All figures are computed from Arbutus Biopharma Corporation's official SEC filings (10-K and 10-Q), covering 15 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.